XML 31 R15.htm IDEA: XBRL DOCUMENT v3.25.0.1
EARNINGS PER SHARE
12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.
The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the years ended December 31, 2024, 2023 and 2022 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share.
The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:
Year Ended December 31,
202420232022
Warrants
Stock option awards854,5451,214,560629,690
Restricted stock awards376,743340,331205,652
Performance stock unit awards286,881
The following tables present the Company’s basic and diluted earnings per share and shares outstanding (in thousands, except per share data):
Year Ended December 31,
 202420232022
Numerator:  
Net income (1) (2)$211,823 $267,090 $150,556 
Denominator:  
Weighted average number of common shares outstanding171,567 178,973 181,105 
Earnings per Common Share:
Earnings per common share, basic$1.23 $1.49 $0.83 

Year Ended December 31,
 202420232022
Numerator:  
Net income (1) (2)$211,823 $267,090 $150,556 
Denominator:  
Weighted average number of common shares outstanding171,567 178,973 181,105 
Effect of dilutive securities1,278 1,402 970 
Weighted average number of common shares outstanding, diluted172,845 180,375 182,075 
Earnings per Common Share:
Earnings per common share, diluted$1.23 $1.48 $0.83 

(1) Net income for the year ended December 31, 2023 includes $63.1 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes. See Note 3, Business Acquisitions and Divestitures, for further discussion.
(2) Net income for the year ended December 31, 2022 includes the impact of the Company’s Respiratory Therapy Asset Sale. See Note 3, Business Acquisitions and Divestitures, for further discussion.